NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 15 September 2021

**Location:** Zoom Video Conference

## Attendees

Committee members present

1. Peter Jackson (Chair) Present for all items
2. Paul Arundel (Vice Chair) Present for all items
3. Ron Akehurst Present for all items
4. Sotiris Antoniou Present for all items
5. Sarah Davis Present for all items
6. Sofia Dias Present for items 5 to 6
7. Bernard Khoo Present for items 5 to 6
8. Jeremy Manuel Present for all items
9. Shehla Mohammed Present for all items
10. Malcolm Oswald Present for items 5 to 6
11. Francis Pang Present for all items
12. Mark Sheehan Present for all items
13. Matt Smith Present for all items
14. Lesley Stewart Present for all items
15. Karen Whitehead Present for all items

NICE staff present

Jasdeep Hayre, Associate director Present for all items

Gavin Kenny, Project manager Present for all items

Ismahan Abdullah, Administrator Present for all items

Sophie McHugh, Administrator Present for all items

Heidi Livingstone,

Senior Public Involvement Adviser Present for items 1 to 4.2

Helen Barnett, Senior Medical Editor Present for all items

Phil Ranson, Communications Manager Present for all items

Lucinda Evans, Coordinator Present for items 1 to 4.2

Fatima Chunara, Technical Analyst Present for all items

Nicola Hay, Technical Advisor Present for all items

Stephen Norton, Technical Analyst Present for all items

 Present for all items

External Group representatives present

Dr G.J Melendez-Tores,

Professor of Clinical and Social Epidemiology, PenTAG

 Present for items 1 to 4.2

Mr Brian O’Toole, Research Fellow, PenTAG Present for items 1 to 4.2

James Mahon, LRiG Present for items 5 to 5.2

Sarah Nevitt, Research Associate, LRiG Present for items 5 to 5.2

Experts present

Professor David Rees, Clinical Expert,

King’s College Hospital Present for items 1 to 4.2

Penelope Stein, Clinical expert

The British Porphyria Association & Alnylam Pharmaceuticals

 Present for items 1 to 4.2

Salman Fatmi, Patient expert

British Porphyria Association Present for items 1 to 4.2

Liz Gill, Patient expert

British Porphyria Association Present for items 5 to 5.2

Yvonne Summers, Clinical expert Present for items 5 to 5.2

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 5 August 2021.

### Evaluation of ID1549 Givosiran for treating acute hepatic porphyria

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Alnylam Pharmaceuticals.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Mark Sheehan declared a financial interest as he was a paid ethics consultant to Alnylam regarding an Early Access Program for a different product.
* It was agreed that his declaration would not prevent Mark Sheehan from participating in this section of the meeting.
* ProfessorDavid Rees declared a financial interest as he has been paid by Alnylam to travel to and speak at meetings since about 2015 and has sat on advisory boards for Alnylam and is the PI on two interventional clinical trials run by Alnylam in the UK and one observational study.
* It was agreed that his declaration would not prevent ProfessorDavid Rees from participating in this section of the meeting.
	+ 1. The Chair, Peter Jackson, led a discussion of the evidence presented to the committee. This information was presented to the committee by Peter Jackson.
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Evaluation Determination (FED). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Final Evaluation Determination (FED) in line with their decisions.

### Appraisal of ID3743 Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Eli Lilly and Company Limited.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
		3. The Chair, Peter Jackson led a discussion of the evidence presented to the committee. This information was presented to the committee by Peter Jackson.
		4. The committee discussed confidential information submitted for this item.
	2. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Evaluation Determination (FED). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Final Evaluation Determination (FED) in line with their decisions.

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Wednesday 6 October 2021 and will start promptly at 9:00am.